RGFP966 inactivation of the YAP pathway attenuates cardiac dysfunction induced by prolonged hypothermic preservation.
- Author:
Xiao-He ZHENG
1
;
Lin-Lin WANG
1
;
Ming-Zhi ZHENG
2
;
Jin-Jie ZHONG
1
;
Ying-Ying CHEN
1
;
Yue-Liang SHEN
1
Author Information
- Publication Type:Journal Article
- Keywords: Hypothermic preservation; RGFP966; Yes-associated protein (YAP); Oxidative stress; Apoptosis
- MeSH: Acrylamides/pharmacology*; Animals; Apoptosis/drug effects*; Cryopreservation; Disaccharides/pharmacology*; Electrolytes/pharmacology*; Glutamates/pharmacology*; Glutathione/pharmacology*; Heart/physiology*; Heart Transplantation/methods*; Hepatocyte Growth Factor/antagonists & inhibitors*; Histidine/pharmacology*; Histone Deacetylase Inhibitors/pharmacology*; Intracellular Signaling Peptides and Proteins/antagonists & inhibitors*; Male; Mannitol/pharmacology*; Oxidative Stress/drug effects*; Phenylenediamines/pharmacology*; Proto-Oncogene Proteins/antagonists & inhibitors*; Rats; Rats, Sprague-Dawley; Signal Transduction/drug effects*; YAP-Signaling Proteins
- From: Journal of Zhejiang University. Science. B 2020;21(9):703-715
- CountryChina
- Language:English
- Abstract: Oxidative stress and apoptosis are the key factors that limit the hypothermic preservation time of donor hearts to within 4-6 h. The aim of this study was to investigate whether the histone deacetylase 3 (HDAC3) inhibitor RGFP966 could protect against cardiac injury induced by prolonged hypothermic preservation. Rat hearts were hypothermically preserved in Celsior solution with or without RGFP966 for 12 h followed by 60 min of reperfusion. Hemodynamic parameters during reperfusion were evaluated. The expression and phosphorylation levels of mammalian STE20-like kinase-1 (Mst1) and Yes-associated protein (YAP) were determined by western blotting. Cell apoptosis was measured by the terminal deoxynucleotidyl-transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) method. Addition of RGFP966 in Celsior solution significantly inhibited cardiac dysfunction induced by hypothermic preservation. RGFP966 inhibited the hypothermic preservation-induced increase of the phosphorylated (p)-Mst1/Mst1 and p-YAP/YAP ratios, prevented a reduction in total YAP protein expression, and increased the nuclear YAP protein level. Verteporfin (VP), a small molecular inhibitor of YAP-transcriptional enhanced associate domain (TEAD) interaction, partially abolished the protective effect of RGFP966 on cardiac function, and reduced lactate dehydrogenase activity and malondialdehyde content. RGFP966 increased superoxide dismutase, catalase, and glutathione peroxidase gene and protein expression, which was abolished by VP. RGFP966 inhibited hypothermic preservation-induced overexpression of B-cell lymphoma protein 2 (Bcl-2)-associated X (Bax) and cleaved caspase-3, increased Bcl-2 mRNA and protein expression, and reduced cardiomyocyte apoptosis. The antioxidant and anti-apoptotic effects of RGFP966 were cancelled by VP. The results suggest that supplementation of Celsior solution with RGFP966 attenuated prolonged hypothermic preservation-induced cardiac dysfunction. The mechanism may involve inhibition of oxidative stress and apoptosis via inactivation of the YAP pathway.
